PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Beta-lactams – Market size and forecast 2018-2023
• Peptides – Market size and forecast 2018-2023
• Quinolones – Market size and forecast 2018-2023
• Macrolides – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Allergan Plc
• Bayer AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of vendors classification
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Beta-lactams – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Beta-lactams – Year-over-year growth 2019-2023 (%)
Exhibit 21: Peptides – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Peptides – Year-over-year growth 2019-2023 (%)
Exhibit 23: Quinolones – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Quinolones – Year-over-year growth 2019-2023 (%)
Exhibit 25: Macrolides – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Macrolides – Year-over-year growth 2019-2023 (%)
Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: North America – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in North America
Exhibit 42: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 43: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in Europe
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc – Vendor overview
Exhibit 54: Allergan Plc – Business segments
Exhibit 55: Allergan Plc – Organizational developments
Exhibit 56: Allergan Plc – Geographic focus
Exhibit 57: Allergan Plc – Segment focus
Exhibit 58: Allergan Plc – Key offerings
Exhibit 59: Bayer AG – Vendor overview
Exhibit 60: Bayer AG – Business segments
Exhibit 61: Bayer AG – Organizational developments
Exhibit 62: Bayer AG – Geographic focus
Exhibit 63: Bayer AG – Segment focus
Exhibit 64: Bayer AG – Key offerings
Exhibit 65: GlaxoSmithKline Plc – Vendor overview
Exhibit 66: GlaxoSmithKline Plc – Business segments
Exhibit 67: GlaxoSmithKline Plc – Organizational developments
Exhibit 68: GlaxoSmithKline Plc – Geographic focus
Exhibit 69: GlaxoSmithKline Plc – Segment focus
Exhibit 70: GlaxoSmithKline Plc – Key offerings
Exhibit 71: Merck & Co. Inc. – Vendor overview
Exhibit 72: Merck & Co. Inc. – Business segments
Exhibit 73: Merck & Co. Inc. – Organizational developments
Exhibit 74: Merck & Co. Inc. – Geographic focus
Exhibit 75: Merck & Co. Inc. – Segment focus
Exhibit 76: Merck & Co. Inc. – Key offerings
Exhibit 77: Pfizer Inc. – Vendor overview
Exhibit 78: Pfizer Inc. – Business segments
Exhibit 79: Pfizer Inc. – Organizational developments
Exhibit 80: Pfizer Inc. – Geographic focus
Exhibit 81: Pfizer Inc. – Segment focus
Exhibit 82: Pfizer Inc. – Key offerings
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of vendors classification
【掲載企業】
Allergan Plc、Bayer AG、GlaxoSmithKline Plc、Merck & Co. Inc.、Pfizer Inc.
【免責事項】
https://www.marketreport.jp/reports-disclaimer